Your browser doesn't support javascript.
loading
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Pavlasova, Gabriela; Borsky, Marek; Seda, Vaclav; Cerna, Katerina; Osickova, Jitka; Doubek, Michael; Mayer, Jiri; Calogero, Raffaele; Trbusek, Martin; Pospisilova, Sarka; Davids, Matthew S; Kipps, Thomas J; Brown, Jennifer R; Mraz, Marek.
Afiliação
  • Pavlasova G; Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Borsky M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Seda V; Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Cerna K; Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Osickova J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Doubek M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Calogero R; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy;
  • Trbusek M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Pospisilova S; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
  • Kipps TJ; Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA.
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and.
  • Mraz M; Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;
Blood ; 128(12): 1609-13, 2016 09 22.
Article em En | MEDLINE | ID: mdl-27480113
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B / Regulação Neoplásica da Expressão Gênica / Antígenos CD20 / Receptores CXCR4 / Quimiocina CXCL12 Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B / Regulação Neoplásica da Expressão Gênica / Antígenos CD20 / Receptores CXCR4 / Quimiocina CXCL12 Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article